Cetuximab

Cetuximab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Metastatic Colorectal Adenocarcinoma、Recurrent Colorectal Adenocarcinoma、Refractory Colorectal Adenocarcinoma、Stage IV Colorectal Cancer AJCC v8。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Cetuximab 研究

• Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.

  II 期招募中中国NCT07044921

• Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

  III 期招募中中国NCT06008119

• Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

  II 期招募中中国NCT06928584

• Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU

  II 期招募中中国NCT07391618

• A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

  I 期 / II 期招募中美国ChileIsrael日本NCT05584670

• A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM

  II 期招募中中国NCT06590259

• Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.

  III 期招募中中国NCT07595276

• A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

  I 期招募中美国澳大利亚加拿大NCT06764771

• Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer

  II 期招募中西班牙NCT06207656

• Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab

  II 期招募中中国NCT06540326

• New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer

  II 期招募中中国NCT07559760

• BBO-11818 in Adult Subjects With KRAS Mutant Cancer

  I 期招募中美国澳大利亚NCT06917079

• A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

  II 期招募中美国澳大利亚比利时BrazilNCT07415031

• Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)

  II 期招募中中国NCT07183865

• A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

  II 期招募中美国澳大利亚加拿大ChileNCT07209111

• Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)

  III 期招募中美国Puerto RicoNCT07702032

• FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

  I 期招募中美国NCT06241456

• Molecular-Based Selection of Patients with Head and Neck Squamous Cell Carcinoma: Biomarker Analysis

  不适用招募中意大利NCT06905145

• Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin

  III 期招募中美国NCT07441681

• Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N

  II 期招募中法国NCT06640725

• Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer

  II 期招募中中国NCT06856187

• FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis

  II 期招募中中国NCT06988852

• Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer

  III 期招募中RussiaNCT06226857

• Quantifying Systemic Immunosuppression to Personalize Cancer Therapy

  不适用招募中意大利NCT05621837

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。